# Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

> **NCT01213979** · PHASE1 · COMPLETED · sponsor: **Pharmacosmos A/S** · enrollment: 16 (actual)

## Conditions studied

- Non-hematological Malignancies

## Interventions

- **DRUG:** 500 mg iron isomaltoside 1000
- **DRUG:** 1000 mg iron isomaltoside 1000

## Key facts

- **NCT ID:** NCT01213979
- **Lead sponsor:** Pharmacosmos A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-07
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213979, "Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01213979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*